Dedicated QT Study in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis
Status:
Completed
Trial end date:
2018-03-06
Target enrollment:
Participant gender:
Summary
This study is a Phase 4, open-label, single group study in which at least 40 adult patients
undergoing miltefosine treatment for mucocutaneous leishmaniasis (CL and ML) will be assessed
by 12-lead ECG for prolongation of the corrected QT interval